Xenpozyme (olipudase alfa) - Coverage Criteria
Medical necessity and prior authorization criteria for intravenous Xenpozyme (olipudase alfa) to treat non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) for adult and pediatric members.
Added initiation criteria to continuation criteria.
Updated diagnosis confirmation and disease manifestation criteria.
Added documentation requirement and administrative updates.
Coverage Criteria for Xenpozyme (olipudase alfa)
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.